Reversal of hypopigmentation in phenylketonuria mice by adenovirus-mediated gene transfer.
Phenylketonuria (PKU) is caused by deficiency of phenylalanine hydroxylase (PAH) in the liver. Patients with PKU show increased L-phenylalanine in blood, which leads to mental retardation and hypopigmentation of skin and hair. As a step toward gene therapy for PKU, we constructed a replication-defective, E1/E3-deleted recombinant adenovirus harboring human PAH cDNA under the control of a potent CAG promoter. When a solution containing 1.2 x 10(9) plaque-forming units of the recombinant adenovirus was infused into tail veins of PKU model mice (Pah(enu2)), predominant expression of PAH activity was observed in the liver. The gene transfer normalized the serum phenylalanine level within 24 h. However, it also provoked a profound host immune response against the recombinant virus; as a consequence, the biochemical changes lasted for only 10 d and rechallenge with the virus failed to reduce the serum phenylalanine concentration. Administration of an immunosuppressant, FK506, to mice successfully blocked the host immune response, prolonged the duration of gene expression to more than 35 d, and allowed repeated gene delivery. We noted a change in coat pigmentation from grayish to black after gene delivery. The current study is the first to demonstrate the reversal of hypopigmentation, one of the major clinical phenotypes of PKU in mice as well as in humans, by adenovirus-mediated gene transfer, suggesting the feasibility of gene therapy for PKU.
Nagasaki
Y
Y
Department of Medical Genetics, Tohoku University School of Medicine, Sendai, Japan.
Matsubara
Y
Y
Takano
H
H
Fujii
K
K
Senoo
M
M
Akanuma
J
J
Takahashi
K
K
Kure
S
S
Hara
M
M
Kanegae
Y
Y
Saito
I
I
Narisawa
K
K
D000256:Adenoviridae; D000818:Animals; D019556:COS Cells; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D006801:Humans; D017496:Hypopigmentation / Q000209:etiology* / Q000628:therapy*; D008099:Liver / Q000187:drug effects / Q000473:pathology; D051379:Mice; D008817:Mice, Mutant Strains; D010649:Phenylalanine / Q000097:blood; D010651:Phenylalanine Hydroxylase / Q000172:deficiency / Q000235:genetics* / Q000378:metabolism; D010661:Phenylketonurias / Q000503:physiopathology / Q000628:therapy*; D011994:Recombinant Proteins / Q000378:metabolism; D016559:Tacrolimus / Q000494:pharmacology; D013997:Time Factors; D014162:Transfection / Q000379:methods*
D011994:Recombinant Proteins; D010649:Phenylalanine; D010651:Phenylalanine Hydroxylase; D016559:Tacrolimus